Brusselle GG, Koppelman GH. N Engl J Med. 2022;386(2):157-171.
Pavord ID, et al. J Allergy Clin Immunol Pract. 2022;10(2):410-419.
Wang E, Wechsler ME. Ann Allergy Asthma Immunol. 2022;128(4):379-389.
Chan R, et al. J Allergy Clin Immunol Pract. 2022;10(6):1497-1505.
Most JF, et al. J Allergy Clin Immunol Pract. 2021;9(10):3662-3671.
Burchard EG, Borrell LN. N Engl J Med. 2021; 385(24):2297-2298.
Panettieri RA Jr, et al. Ann Allergy Asthma Immunol. 2022;129(4):467−474.
How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit.
Pepper AN, et al. J Allergy Clin Immunol Pract. 2021;9(3):1081-1088.
Couillard Castonguay S, Pavord ID. Biological therapies for asthma. In: Janes S, ed. Encyclopedia of Respiratory Medicine. 2nd ed. Alpharetta, GA: Elsevier B.V.; 2021: 411-434.
Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809.
Wechsler ME, et al. N Engl J Med. 2021;385(18):1656-1668.
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial.
Davidescu L, et al. J Asthma Allergy. 2022;15:737-747.
Cahill KN, et al. N Engl J Med. 2017;376(20):1911-1920.
Busse WW, et al. J Allergy Clin Immunol Pract. 2022;10(1):229-230.
Clinical outcomes and emergency health care utilization in patients with severe asthma who continued, switched, or stopped biologic therapy: results from the CLEAR study.
Ali N, et al. CHEST. 2022; 162(suppl 4):A23-A27.
Clinical Practice Tools
These tools for asthma control were created following the evidence-based guidance published by the National Institutes of Health.
This 5-question test evaluates asthma control over the past 4 weeks on a 5-point Likert scale. A score of <20 on the ACT suggests asthma that is uncontrolled.
Nathan RA, et al. J Allergy Clin Immunol. 2004;113(1):59-65.
This 7-question assessment tool measures asthma control over the past 7 days. Six questions are self-administered by the patient, and 1 question requires a clinician’s input. Scores range from 1 (totally controlled) to 6 (severely uncontrolled).
Juniper EF, et al. Eur Respir J. 1999;14(4):902-907.
This 4-question test assesses asthma control over the past 4 weeks. Each question has a possible score of 0 or 1; if the sum of the 4 question scores is >1, the patient’s asthma may be uncontrolled.
Vollmer WM, et al. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1647-1652.
The CHEST Foundation, Allergy and Asthma Network, and American College of Allergy, Asthma & Immunology (ACAAI) have developed a shared decision-making tool for adults with severe asthma so that they may work collaboratively with clinicians to improve self-management skills, choose the best treatment plan, and increase adherence.
Patient Advocacy Organizations and Resources
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.
The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.
The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health.
New Horizons in Severe Asthma
From the Airway Epithelium to Improved Patient Outcomes
|Faculty:||Monica Kraft, MD; Erika Gonzalez, MD; Jonathan Corren, MD|